1. Home
  2. Analysis
  3. Linagliptin
  4. Butrans

Linagliptin and Butrans drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Linagliptin (linagliptin) and Butrans (buprenorphine). Common drug interactions include fall among females and glomerular filtration rate decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Linagliptin and Butrans. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Linagliptin?

Linagliptin has active ingredients of linagliptin. eHealthMe is studying from 8,112 Linagliptin users. Check the latest studies of Linagliptin.

What is Butrans?

Butrans has active ingredients of buprenorphine. It is often used in pain. eHealthMe is studying from 64,148 Butrans users. Check the latest studies of Butrans.

On Jul, 08, 2026

16 people who take Linagliptin and Butrans together, and have interactions are studied.

Linagliptin and Butrans drug interactions.

What are the common drug interactions of Linagliptin and Butrans, by gender? *:

female:

  1. Fall
  2. Muscle twitching
  3. Seizure (abnormal excessive or synchronous neuronal activity in the brain)
  4. Subdural haemorrhage (bleeding between the skull and the surface of the brain)
  5. Renal failure acute (rapid kidney dysfunction)
  6. Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)
  7. Alanine aminotransferase increased
  8. Blood creatine phosphokinase increased
  9. Breast cancer
  10. Lethargy (tiredness)

male:

  1. Glomerular filtration rate decreased
  2. Hyperkalaemia (damage to or disease of the kidney)

What are the common drug interactions of Linagliptin and Butrans, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Glomerular filtration rate decreased
  2. Hyperkalaemia (damage to or disease of the kidney)
  3. Muscle twitching
  4. Seizure (abnormal excessive or synchronous neuronal activity in the brain)
  5. Subdural haemorrhage (bleeding between the skull and the surface of the brain)
  6. Renal failure acute (rapid kidney dysfunction)
  7. Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)
  8. Alanine aminotransferase increased
  9. Blood creatine phosphokinase increased
  10. Lethargy (tiredness)

What are the existing conditions these people have? *

  1. High Blood Cholesterol: 5 people, 31.25%
  2. Cystic Fibrosis (disease of the secretary glands): 3 people, 18.75%
  3. Peripheral Swelling: 1 person, 6.25%
  4. Lymphoma (cancer that begins in immune system cells): 1 person, 6.25%
  5. Hypersensitivity: 1 person, 6.25%
  6. Affective Disorder (mental disorder): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Linagliptin and Butrans?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Linagliptin and Butrans:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Linagliptin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Butrans:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Linagliptin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Butrans and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on linagliptin and buprenorphine (the active ingredients of Linagliptin and Butrans, respectively), and Linagliptin and Butrans (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.